Russell Investments Boosts Stake in Eli Lilly

Asset manager increases holdings in pharmaceutical giant by 5.2% in Q3

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Russell Investments Group Ltd. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% during the third quarter, according to a recent SEC filing. The firm now owns 586,898 shares of the company's stock, making it Eli Lilly's 19th largest institutional shareholder.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, with a diverse portfolio of innovative medicines. Institutional investors closely watch changes in major shareholders as it can signal confidence or concerns about the company's future performance.

The details

According to the filing, Russell Investments acquired an additional 29,188 shares of Eli Lilly in the third quarter, bringing its total position to 586,898 shares. This represents approximately 0.06% of Eli Lilly's outstanding shares and is valued at around $444.6 million based on the company's current stock price.

  • Russell Investments filed the 13F report with the SEC on March 9, 2026, disclosing its Q3 2025 holdings.

The players

Russell Investments Group Ltd.

A global asset management firm that oversees over $2 trillion in assets for institutional and individual investors worldwide.

Eli Lilly and Company

A multinational pharmaceutical company that develops and markets drugs in various therapeutic areas, including diabetes, oncology, neuroscience, and immunology.

Got photos? Submit your photos here. ›

The takeaway

Russell Investments' increased stake in Eli Lilly suggests the asset manager sees continued growth potential in the pharmaceutical company's business. As a major institutional investor, Russell's portfolio moves are closely watched by the market.